Hyderabad, March 27 -- Hetero, a leading global pharmaceutical company, on Friday announced the export launch of its generic semaglutide injection portfolio to expand access to treatments for type 2 diabetes and obesity across global markets.
The injectable therapies will be marketed under the brand names Truglyx, Rolmodl and Moto G, with initial rollouts underway in Africa, Asia and the Middle East, the Hyderabad based pharmaceutical company said in a statement here.
The company plans a phased expansion to over 75 countries as part of its multi-year global strategy.
Semaglutide belongs to the GLP-1 class of therapies used in managing diabetes and weight-related conditions.
The launch aims to improve access to affordable, high-quality c...